Our results demonstrate that pitavastatin and L-glutamine in combination could ameliorate T2D manifestations by (1) improving glucose tolerance and insulin sensitivity, (2) normalizing the insulin and adiponectin levels, (3) inhibiting gluconeogenesis, reducing hepatic GLUT2 and enhancing glycolysis, and glycogen synthesis, (4) increasing the IR1β, pAkt, and AdipoR1 expression levels in skeletal muscle, (5) increasing mitochondrial biogenesis and ETC activities, and (6) increasing β-cell regeneration by proliferation (Figure 10). Here, ADIPOQ is linked to type 2 diabetes mellitus.